Frank Scholz - Mallinckrodt Public Insider

Mallinckrodt Public Limited Company -- USA Stock  

USD 16.09  0.32  2.03%

Sr. VP of Global Operations

Dr. Frank Scholz is Executive Vice President of Global Operations and President Specialty Generics of Mallinckrodt Public Limited Company. His responsibilities include global manufacturing operations, quality and supply chain, as well as the Specialty Generics segment. He joined Mallinckrodt in March 2014 as Senior Vice President of Global Operations and assumed his current position in September 2016. Prior to joining Mallinckrodt, Dr. Scholz was a partner with McKinsey Co, a global management consulting firm first in its Hamburg, Germany office and then in its Chicago, Illinois office
Age: 46  SVP Since 2016  Ph.D    
44 17 8463 6700
Scholz was a leader in McKinsey?s global pharmaceutical and operations practices. He joined McKinsey in 1997. Prior to joining McKinsey, Dr. Scholz was a research assistant at the Institute for Management and Accounting at the University of Hanover, Germany.

Frank Scholz Latest Insider Activity

Management Efficiency

The company has Return on Asset of 2.16 % which means that on every $100 spent on asset it made $2.16 of profit. This is way below average. In the same way, it shows return on shareholders equity (ROE) of 30.79 % implying that it generated $30.79 on every 100 dollars invested.
The company has 6.73 B in debt with debt to equity (D/E) ratio of 103.2 . This implies that the company may be unable to create cash to meet all of its financial commitments. Mallinckrodt Public Limited Company has Current Ratio of 2.14 demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due.

Entity Summary

Mallinckrodt public limited company develops, manufactures, markets, and distributes branded pharmaceutical products in Canada and the European Union, as well as in Latin American, the Middle Eastern, African, and the Asia-Pacific regions. The company is based in Staines-Upon-Thames, the United Kingdom. Mallinckrodt Public operates under Drugs - Generic classification in USA and traded on New York Stock Exchange. It employs 00 people.Mallinckrodt Public Limited Company (MNK) is traded on New York Stock Exchange in USA. It is located in IRELAND and employs 3,900 people. Mallinckrodt Public is listed under Pharmaceutical Products category by Fama And French industry classification.

Did you try this?

Run Fundamentals Comparison Now

Fundamentals Comparison

Compare fundamentals across multiple equities to find investing opportunities
Hide  View All  NextLaunch Fundamentals Comparison
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Mallinckrodt Public Limited Company to your portfolio

Top Management

Mallinckrodt Public Leadership Team
David Carlucci, Director
Frank Scholz, SVP, Ph.D
Hugh ONeill, President
Gary Phillips, President
Martin Carroll, Director, MBA
Steven Romano, President, Ph.D
Steve Romano, President, Ph.D
Mark Trudeau, CEO
Kneeland Youngblood, Director, Ph.D
Mark Casey, Executive
JoAnn Reed, Director, MBA
Virgil Thompson, Director
Meredith Fischer, President
Terrance Carlson, President
Ian Watkins, SVP
Melvin Booth, Chairman, CPA
Raymond Furey, President
Diane Gulyas, Director
Angus Russell, Director, Ph.D
Ronald Lloyd, President
Joseph Zaccagnino, Director
Matthew Harbaugh, CFO
MichaelBryant Hicks, Executive

Stock Performance

Mallinckrodt Public Performance Indicators